BRISTOL MYERS SQUIBB CO
BMYPharmaceutical Preparations · SIC 2834 · CIK 0000014272
Revenue FY2025
$48.19B
Net Income
$7.05B
EPS (Basic)
$3.47
Net Margin
14.6%
ROE
38.2%
Total Equity
$18.47B
Shares Out
2.04B
BRISTOL MYERS SQUIBB CO — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2007–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 13 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Kahn Brothers Group
Kahn Brothers
$10.0M
2.0%
+2.2%
Hillman Capital Management
Hillman
$2.6M
1.3%
(14.8%)
Pzena Investment Management
Richard Pzena
$979.9M
1.2%
(0.5%)
Miller Value Partners
Bill Miller
$4.0M
1.0%
—
Motley Fool Asset Management
Motley Fool Asset Management
$10.1M
0.4%
(0.6%)
Ariel Investments
John Rogers
$40.1M
0.3%
(3.5%)
OrbiMed Advisors
OrbiMed Advisors
$53.3M
0.3%
—
Adage Capital Management
Adage Capital Management
$98.9M
0.1%
+17.0%
Alps Advisors
Alps Advisors
$32.2M
0.1%
+15.3%
Tweedy Browne
Tweedy Browne
$2.2M
0.0%
+43.6%
Capital World Investors
Capital World Investors
$129.3M
0.0%
+0.9%
Mairs & Power
Mairs & Power
$1.4M
0.0%
+2.0%
Dodge & Cox
Dodge & Cox
$2.4M
0.0%
(99.1%)
Insider Transactions
Reading stored insider transactions…